Telephone
61.3.9349.4906
Address
Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000
Description
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$2,989.00
1 week
0%
1 month
-42.86%
YTD
-60%
1 year
-60%
All time high
1.5
EPS 3 yr Growth
-62.000%
EBITDA Margin
N/A
Operating Cashflow
-$20m
Free Cash Flow Return
-68.60%
ROIC
-47.20%
Interest Coverage
N/A
Quick Ratio
6.20
Shares on Issue (Fully Dilluted)
2440m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Appendix 4C and Quarterly Cash Flow Report
×
Appendix 4C and Quarterly Cash Flow Report |
31 August 23 |
Alterity Presents New Data on Multiple System Atrophy
×
Alterity Presents New Data on Multiple System Atrophy |
31 August 23 |
Appendix 4E and Annual Report 2023
×
Appendix 4E and Annual Report 2023 |
31 August 23 |
Appendix 4G and Corporate Governance Statement 2023
×
Appendix 4G and Corporate Governance Statement 2023 |
31 August 22 |
Appendix 4E & Annual Report 2022
×
Appendix 4E & Annual Report 2022 |
31 August 22 |
Appendix 4G and Corporate Governance Statement 2022
×
Appendix 4G and Corporate Governance Statement 2022 |
30 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 May 23 |
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
×
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder |
30 June 22 |
Alterity receives a $4.1 million R&D Tax Refund
×
Alterity receives a $4.1 million R&D Tax Refund |
30 January 23 |
ATH434 Prevents Brain Cell loss in Parkinsons Animal Model
×
ATH434 Prevents Brain Cell loss in Parkinsons Animal Model |
30 August 19 |
Appendix 4E & Annual Report 2019
×
Appendix 4E & Annual Report 2019 |
29 December 22 |
New US patent for compounds to treat neurodegeneration
×
New US patent for compounds to treat neurodegeneration |
29 April 22 |
Appendix 4C and Quarterly Cash Flow Report
×
Appendix 4C and Quarterly Cash Flow Report |
28 September 22 |
Change in substantial holding
×
Change in substantial holding |
28 October 22 |
Appendix 4C and Quarterly Cash Flow Report
×
Appendix 4C and Quarterly Cash Flow Report |
28 January 22 |
New publication shows ATH434 rescues neurons in MSA model
×
New publication shows ATH434 rescues neurons in MSA model |
28 February 23 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
28 February 22 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
27 November 23 |
ATH presents Novel Biomarker Data for Evaluation of MSA
×
ATH presents Novel Biomarker Data for Evaluation of MSA |
27 June 22 |
Notification of cessation of securities - ATH
×
Notification of cessation of securities - ATH |
27 January 22 |
Appendix 4C and Quarterly Cash Flow Report
×
Appendix 4C and Quarterly Cash Flow Report |
27 April 23 |
Appendix 4C and Quarterly Cash Flow Report
×
Appendix 4C and Quarterly Cash Flow Report |
27 April 22 |
UK Regulatory Authorisation to Proceed with Phase 2 Trial
×
UK Regulatory Authorisation to Proceed with Phase 2 Trial |
26 September 22 |
Wearable Sensor Data from bioMUSE Natural History Study
×
Wearable Sensor Data from bioMUSE Natural History Study |
26 October 22 |
Presentation of bioMUSE MRI data
×
Presentation of bioMUSE MRI data |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.